Nitric oxide in kidney transplantation
- PMID: 37722191
- DOI: 10.1016/j.biopha.2023.115530
Nitric oxide in kidney transplantation
Abstract
Kidney transplantation is the treatment of choice for patients with kidney failure. Compared to dialysis therapy, it provides better quality of life and confers significant survival advantage at a relatively lower cost. However, the long-term success of this life-saving intervention is severely hampered by an inexorable clinical problem referred to as ischemia-reperfusion injury (IRI), and increases the incidence of post-transplant complications including loss of renal graft function and death of transplant recipients. Burgeoning evidence shows that nitric oxide (NO), a poisonous gas at high concentrations, and with a historic negative public image as an environmental pollutant, has emerged as a potential candidate that holds clinical promise in mitigating IRI and preventing acute and chronic graft rejection when it is added to kidney preservation solutions at low concentrations or when administered to the kidney donor prior to kidney procurement and to the recipient or to the reperfusion circuit at the start and during reperfusion after renal graft preservation. Interestingly, dysregulated or abnormal endogenous production and metabolism of NO is associated with IRI in kidney transplantation. From experimental and clinical perspectives, this review presents endogenous enzymatic production of NO as well as its exogenous sources, and then discusses protective effects of constitutive nitric oxide synthase (NOS)-derived NO against IRI in kidney transplantation via several signaling pathways. The review also highlights a few isolated studies of renal graft protection by NO produced by inducible NOS.
Keywords: Endothelial nitric oxide synthase (eNOS); Inducible nitric oxide synthase (iNOS); Kidney transplantation; Neuronal nitric oxide synthase (nNOS); Nitric oxide (NO).
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
-
Lipopolysaccharide-induced cross-tolerance against renal ischemia-reperfusion injury is mediated by hypoxia-inducible factor-2α-regulated nitric oxide production.Kidney Int. 2014 Feb;85(2):276-88. doi: 10.1038/ki.2013.342. Epub 2013 Sep 11. Kidney Int. 2014. PMID: 24025643
-
Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion.Am J Physiol Renal Physiol. 2009 Jan;296(1):F25-33. doi: 10.1152/ajprenal.90531.2008. Epub 2008 Oct 29. Am J Physiol Renal Physiol. 2009. PMID: 18971208
-
Protective effect of nitric oxide on hepatopulmonary syndrome from ischemia-reperfusion injury.World J Gastroenterol. 2012 Jul 7;18(25):3310-6. doi: 10.3748/wjg.v18.i25.3310. World J Gastroenterol. 2012. PMID: 22783057 Free PMC article.
-
New progress in roles of nitric oxide during hepatic ischemia reperfusion injury.World J Gastroenterol. 2017 Apr 14;23(14):2505-2510. doi: 10.3748/wjg.v23.i14.2505. World J Gastroenterol. 2017. PMID: 28465634 Free PMC article. Review.
-
[Reduced nitric oxide bioavailability in chronic renal failure: a new factor of progression?].G Ital Nefrol. 2008 May-Jun;25(3):306-16. G Ital Nefrol. 2008. PMID: 18473302 Review. Italian.
Cited by
-
Mesenchymal stem cell-derived exosomes in renal ischemia-reperfusion injury: a new therapeutic strategy.Int Urol Nephrol. 2025 Mar;57(3):875-884. doi: 10.1007/s11255-024-04258-4. Epub 2024 Nov 9. Int Urol Nephrol. 2025. PMID: 39520637 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical